| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Physiology, Structural and Cellular Biology, and Medicine, University of South Alabama, Mobile, Alabama 36688-0002
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Both mitochondrial ATP-sensitive K+ (KATP) channels and the actin cytoskeleton have been proposed to be end-effectors in ischemic preconditioning (PC). For evaluation of the participation of these proposed end effectors, rabbits underwent 30 min of regional ischemia and 3 h of reperfusion. PC by 5-min ischemia + 10-min reperfusion reduced infarct size by 60%. Diazoxide, a mitochondrial KATP-channel opener, administered before ischemia was protective. Protection was lost when diazoxide was given after onset of ischemia. Anisomycin, a p38/JNK activator, reduced infarct size, but protection from both diazoxide and anisomycin was abolished by 5-hydroxydecanoate (5-HD), an inhibitor of mitochondrial KATP channels. Isolated adult rabbit cardiomyocytes were subjected to simulated ischemia by centrifuging the cells into an oxygen-free pellet for 3 h. PC was induced by prior pelleting for 10 min followed by resuspension for 15 min. Osmotic fragility was assessed by adding cells to hypotonic (85 mosmol) Trypan blue. PC delayed the progressive increase in fragility seen in non-PC cells. Incubation with diazoxide or pinacidil was as protective as PC. Anisomycin reduced osmotic fragility, and this was reversed by 5-HD. Interestingly, protection by PC, diazoxide, and pinacidil could be abolished by disruption of the cytoskeleton by cytochalasin D. These data support a role for both mitochondrial KATP channels and cytoskeletal actin in protection by PC.
myocardial infarction; mitogen-activated protein kinases
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
THE NATURE OF THE end effector(s) responsible for ischemic preconditioning's protection has so far proved elusive. However, opening of ATP-sensitive K+ (KATP) channels or changes in the myocyte's actin cytoskeleton have been proposed as two possible candidates.
The KATP-channel blockers glibenclamide and 5-hydroxydecanoate (5-HD) have been reported to block ischemic preconditioning's protection in a variety of species, including rabbits (17, 40, 42), dogs (2, 12), pigs (34), and rats (33). Preconditioning in human tissue also appears to involve KATP channels because glibenclamide could block the effects of ischemic preconditioning and protein kinase C activation in human atrial trabeculae (35). Conversely, KATP-channel openers are cardioprotective. Nicorandil (28), bimakalim (44), and cromakalim (15) reduce infarct size in dogs. Pinacidil can protect rabbit myocytes against simulated ischemia (4). In guinea pig hearts postischemic recovery of function was greatly improved by the KATP-channel openers BMS-180448 and cromakalim (14).
Several discrepancies in the literature have caused investigators to be cautious about accepting the KATP hypothesis, however. It was thought that by opening of sarcolemmal KATP channels, action potential duration (APD) would be shortened, which would reduce calcium loading of the myocyte and hence exert a cardioplegic action (13). However, bimakalim (44), BMS-180448 (14), and cromakalim (15) are protective independent of APD shortening. Furthermore, 5-HD did not block the cromakalim-induced sarcolemmal KATP currents (26), yet it was still able to block the anti-ischemia action of the opener.
Instead, mitochondrial KATP channels may mediate the observed cardiac protection. Garlid et al. (9, 10) have demonstrated that whereas both cromakalim and diazoxide stimulated KATP activity in purified mitochondria, sarcolemmal KATP channels were insensitive to diazoxide. Diazoxide was just as protective in preserving postischemic function in isolated rat hearts as cromakalim (9). In addition, diazoxide-induced protection and cardiac mitochondrial K+ flux could be reversed by 5-HD. Similar results have been obtained in isolated rabbit myocytes (23, 32). Therefore, diazoxide appears to be a selective opener and 5-HD a selective blocker of mitochondrial KATP channels.
There is also evidence to suggest that preconditioning may involve changes in the actin cytoskeleton. Activation of stress-activated protein kinase pathways, p38 mitogen-activated protein (MAP) kinase and JNK, has been documented in preconditioned rabbit (41) and rat (25) hearts. Among other things, this pathway activates MAP kinase-activated protein kinase-2 (MAPKAPK-2). This enzyme can, in turn, phosphorylate the small heat shock protein 27 (HSP27) (5, 36), an important regulator of actin dynamics that promotes polymerization of actin filaments, thus increasing the stability of the cytoskeleton (16, 21). Activation of p38 MAP kinase has been shown to prevent cytochalasin D-induced fragmentation of actin filaments, thus preserving cell viability (16, 18). Brief exposure to adenosine increases p38 MAP kinase activity and HSP27 phosphorylation in cardiomyocytes (20). Furthermore, overexpression of HSP27 in isolated rat ventricular myocytes confers protection against simulated ischemia (24). Because prolonged ischemia is known to cause cytoskeletal disruption (7), activation of the MAPKAPK-2/HSP27 pathway and preservation of the actin filaments could well explain the beneficial action of ischemic preconditioning.
Thus there are suggestive data to support the role of both the KATP channel and the actin cytoskeleton as the end effector in cardioprotection. However, there has not been a systematic analysis of the importance of the mitochondrial KATP channel in the signaling pathway of preconditioning, and no attempt has been made to investigate any possible interaction between these two putative end effectors. Accordingly, the present study tested whether the mitochondrial KATP-channel opener diazoxide could mimic preconditioning in both an anesthetized rabbit infarct size model and isolated cardiomyocytes. Whether protection by anisomycin, a direct activator of the p38 MAP kinase/MAPKAPK-2 pathway, could be prevented by blockade of mitochondrial KATP channels with 5-HD was also examined. Finally, the possible interaction between mitochondrial KATP channels and the cytoskeleton was studied by testing whether disruption of actin filaments with cytochalasin D would affect protection mediated by either ischemic preconditioning, pinacidil, or diazoxide.
| |
MATERIALS AND METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
All procedures were approved by the Institutional Animal Care and Use Committee and were in accordance with recommendations published in the Guide for the Care and Use of Laboratory Animals.
In Situ Rabbit Heart Model
New Zealand White rabbits of either sex weighing between 1.5 and 2.5 kg were anesthetized with pentobarbital sodium (30 mg/kg iv) via a marginal ear vein. A tracheotomy was performed, and the rabbits were ventilated with 100% oxygen using a positive-pressure ventilator at a rate of 30-35 breaths/min and a tidal volume of ~15 ml. The respiratory rate was adjusted to maintain blood pH in the physiological range (pH 7.35-7.45), and a heating pad was placed under the rabbit to maintain rectal temperature between 38 and 39°C. The left carotid artery and jugular vein were cannulated with PE-90 catheters filled with heparinized (10 U/ml) saline for measurement of arterial blood pressure and infusion of anesthetic and drugs, respectively. A left thoracotomy was performed in the fourth intercostal space to expose the heart, and a 2-0 silk suture was passed around a main branch of the left coronary artery to form a snare by passing the ends of the thread through a small vinyl tube. Coronary occlusion was implemented by pulling the snare tight and clamping the tube with a hemostat. Ischemia was confirmed by regional cyanosis. Reperfusion was achieved by releasing the snare and confirmed by visible hyperemia. The animals were allowed to stabilize for 20 min before the start of the experimental protocol.Infarct Size Measurement
At the end of the experiment, the hearts were quickly excised and mounted on a Langendorff apparatus, where they were perfused for 1 min with saline to wash out blood. The snare around the coronary artery was again pulled to reocclude the coronary artery, and 1- to 10-µm zinc cadmium fluorescent particles were infused into the perfusate to demarcate the ischemic (tissue at risk) zone as the tissue without fluorescence under ultraviolet light. The hearts were then weighed and frozen. The frozen hearts were cut into slices 2 mm in thickness. The slices were incubated in 1% triphenyltetrazolium chloride (TTC) in sodium phosphate buffer (pH 7.4) for 20 min at 37°C. TTC stains viable tissue a deep red, whereas necrotic tissue remains unstained and appears tan to brown. The slices were then immersed in 10% Formalin to enhance the contrast between stained and unstained tissue. The areas of infarct and risk zone in each slice were determined by planimetry. The volumes of both regions of each slice were calculated and then summed for the entire heart. The amount of infarction for each heart was expressed as a percentage of the risk (ischemic) zone. Only hearts with a risk zone >0.5 cm3 were included because smaller ischemic zones are associated with small infarcts even in nonpreconditioned hearts (46).Isolated Rabbit Myocyte Model
New Zealand White rabbits of either sex weighing between 1.5 and 2.5 kg were used in these studies. Rabbits were anesthetized and surgically prepared as described above. After exposure of the myocardium, the heart was rapidly excised and mounted on a Langendorff apparatus. The heart was perfused for 5 min with calcium-free buffer containing 90 mM NaCl, 30 mM KCl, 1.2 mM MgCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 10 mM glucose, 20 mM creatine, 60 mM taurine, and 1% BSA and supplemented with basal medium Eagle (BME) vitamin and amino acid mixture. The buffer was then recirculated with 1 mg/ml collagenase and 20 µM CaCl2 for 15 min. The hearts were removed, and the left ventricle was macerated and dispersed in buffer containing 115 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 10 mM glucose, 20 mM creatine, 60 mM taurine, 10 mM HEPES, and 4% BSA and supplemented with BME vitamin and amino acid mixture. After the cells were filtered through nylon mesh, they were washed two to three times and then made calcium tolerant by slowly restoring calcium in the medium to 1.25 mM. All buffers were gassed with 95% O2-5% CO2 and maintained at 37°C. Ischemia was simulated by pelleting the cells (~0.5 ml packed volume) at 200 rpm, and the supernatant was replaced with microballoons to exclude oxygen. Every 30 min for 3 h, a 25-µl aliquot of cells was removed for determination of osmotic fragility by observing whether the cells could exclude trypan blue dye in a hypotonic (85 mosmol) solution. Those cells unable to exclude dye are considered to have undergone membrane failure and are therefore deemed nonviable. Three hundred cells were counted in each sample, and the percentage of stained cells was determined. An index of fragility was calculated as the area under the curve of percent stained cells vs. time.Materials
Anisomycin was obtained from Sigma (St. Louis, MO). Cytochalasin D was purchased from Fluka (Ronkonkoma, NY). 5-HD and diazoxide were purchased from Research Biochemicals International (Natick, MA). Anisomycin was dissolved in DMSO and then diluted in either 0.9% saline or buffer. Cytochalasin D was dissolved in DMSO and diluted in buffer. Diazoxide was dissolved in a vehicle consisting of 1 N sodium hydroxide and 0.9% saline mixed in a 1:3 proportion. 5-HD was dissolved directly in 0.9% saline or buffer.Experimental Protocols
In situ rabbit hearts. Nine groups of in situ hearts were studied, and the timing of interventions is illustrated in Fig. 1. In the control (Con) group, hearts experienced only 30 min of regional ischemia and 3 h of reperfusion. The PC group was ischemically preconditioned by means of 5 min of regional ischemia followed by 10 min of reperfusion before the 30-min ischemia. In the Diaz-Pre group, the selective mitochondrial KATP-channel opener diazoxide (10 mg/kg) was given as an intravenous bolus 10 min before the 30-min occlusion. In the Diaz-Post group, animals received the same dose of diazoxide but the diazoxide injection was delayed until 5 min after the onset of the 30-min ischemic period. Rabbits in the 5-HD group were treated with an intravenous bolus of 5 mg/kg 5-HD, reportedly a selective blocker of mitochondrial KATP channels, 15 min before the 30-min ischemia. In the Aniso(50) and Aniso(100) groups, anisomycin at 50 or 100 µg/kg, respectively, was injected intravenously 10 min before the regional ischemia. In the Diaz + 5-HD and Aniso + 5-HD groups, the protocols for the Diaz-Pre and Aniso(100) groups were combined with the 5-HD protocol.
|
Isolated myocytes. Cells from any given heart were typically divided into six tubes for parallel experiments with the drug and appropriate controls. In total there were 10 groups. In the Con group, myocytes were subjected to only the 3 h of simulated ischemia. In the PC group, preconditioning was induced by 10 min of pelleting followed by 15 min of resuspension in oxygenated buffer before the 3-h pelleting. In the Diaz and Pina groups, either diazoxide (30 µM) or pinacidil (50 µM), respectively, was included in the medium 15 min before the 3-h simulated ischemia. In the Aniso group, anisomycin (50 ng/ml) was included 15 min before the 3-h pelleting. In the 5-HD and Cyto groups, either 5-HD (100 µM) or cytochalasin D (20 µM), respectively, was added to the medium 20 min before simulated ischemia. In the Ox-Con, Ox-5-HD, and Ox-Cyto groups, control cells or 5-HD- or cytochalasin D-treated cells were incubated in oxygenated buffer for 210 min and were not pelleted.
Statistics
All data are expressed as means ± SE. One-way ANOVA combined with Scheffé's post hoc test was used to test for differences in baseline hemodynamics and infarct size between groups. ANOVA with repeated measures was used to test for differences in hemodynamics within any given group. A P value <0.05 was considered to be significant.| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
In Situ Rabbit Hearts
Fifty-four in situ rabbit hearts were prepared for this investigation, with six in each group. Table 1 shows that baseline hemodynamics were not statistically different between groups. Diazoxide (10 mg/kg) injected 10 min before the ischemic period (Diaz-Pre) induced a marked reduction in mean arterial pressure (P < 0.05) without a significant change in heart rate. The peak effect was observed 1 min after injection, with the change in arterial pressure still present (48 ± 5 mmHg, P < 0.05) at the onset of the sustained ischemia. Similar hemodynamic changes were seen when diazoxide was given 5 min into the ischemic period (Diaz-Post). Administration of 5 mg/kg 5-HD 15 min before the ischemic period elicited a small but significant increase in arterial pressure (P < 0.05) but did not affect heart rate. 5-HD had no appreciable effect on the diazoxide-induced hypotension at either 1 or 10 min after the latter's injection. However, combination of the two drugs led to a significant elevation in heart rate by the onset of ischemia (256 ± 15 beats/min, P < 0.05), which was sustained for the remainder of the experiment. Neither dose of anisomycin (50 or 100 µg/kg) had any appreciable hemodynamic effect.
|
Table 2 shows the heart weight and infarct
size data with no apparent differences in body weight, heart weight, or
risk zone size among the various groups. Figure
2 shows that pretreatment with diazoxide 10 min before occlusion was just as protective as ischemic preconditioning
(19.1 ± 4.0 and 16.0 ± 2.1%, respectively; P < 0.05 vs. control). However, when
administration of diazoxide was delayed until 5 min after the onset of
ischemia, the resulting infarct size (30.7 ± 3.9%;
P = NS vs. control) was similar to that in the control group. As expected, prior blockade of mitochondrial KATP channels with 5-HD, which
alone did not change infarct size from control levels (38.9 ± 1.5%),
completely abolished the protective effect of diazoxide given 10 min
before ischemia (37.3 ± 3.8%). A plot of infarct size vs.
risk zone size for these groups is shown in Fig.
3. Anisomycin at 50 µg/kg also reduced
infarct size (21.0 ± 3.9%; P < 0.05), as shown in Fig. 4.
Increasing the dose to 100 µg/kg afforded no additional protection
(21.6 ± 4.1%; P < 0.05). However, the protective effect of the higher dose of anisomycin
was blocked by 5-HD (40.8 ± 3.9%).
|
|
|
|
Isolated Rabbit Cardiomyocytes
Three hours of simulated ischemia caused a progressive increase in the number of cells staining blue in hypotonic trypan blue (Fig. 5). Ischemic preconditioning significantly reduced the number of stained cells present (areas under curve of 61.1 ± 6.9 vs. 76.2 ± 5.6% · h; P < 0.05). However, this protective effect was completely abolished by cytochalasin D (72.7 ± 6.6% · h), which itself did not alter osmotic fragility in pelleted cells (72.9 ± 5.8% · h). A 15-min pretreatment with diazoxide was just as protective as preconditioning (58.9 ± 5.3% · h) (Fig. 6). Similar results were obtained with pinacidil (60.2 ± 4.3% · h; Fig. 7). The reduction in osmotic fragility by both diazoxide and pinacidil could be blocked by cytochalasin D [68.6 ± 5.1% · h (Fig. 6) and 72.0 ± 4.2% · h (Fig. 7), respectively]. Figure 8 shows that anisomycin reduced the number of stained cells (62.0 ± 2.8% · h) compared with controls. However, 5-HD completely reversed this protective effect (72.6 ± 3.4% · h). The survival rate of oxygenated cells treated with either cytochalasin D or 5-HD was no different from oxygenated controls over 3 h.
|
|
|
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Previous studies have shown that adenosine and other receptors trigger ischemic preconditioning in the rabbit heart (11, 22, 27). Subsequent activation and translocation of protein kinase C are then required (29, 45). Downstream signaling components include tyrosine kinase (3) and MAP kinases (43). However, the final effector protein(s) activated during preconditioning have remained controversial.
The observation that the benzopyran derivatives such as cromakalim and bimakalim were able to induce cardioprotection independently of APD shortening suggested that sarcolemmal KATP channels were not the site of action (14, 15, 44). Demonstration that the reportedly selective KATP-channel blocker 5-HD could inhibit protection without affecting activation of sarcolemmal KATP current induced by cromakalim (26) further eroded support of the sarcolemmal channels as the end effector. Garlid et al. (10) reported that diazoxide and cromakalim were able to restore ATP-inhibited K+ flux in bovine cardiac mitochondria. Therefore, cromakalim was also opening the mitochondrial KATP channel within the same concentration range as its protective effect. Hence it was suggested that the protection of openers such as cromakalim was more likely to be related to the drug's action on mitochondrial channels rather than those in the sarcolemma. However, although cromakalim was also a potent activator of cardiac sarcolemmal KATP channels, very high (near millimolar) concentrations of diazoxide were required to open those channels on the surface membrane (9). Therefore, diazoxide is ~2,000-fold more selective for mitochondrial versus sarcolemmal KATP channels.
The present study demonstrates that intravenous injection of diazoxide 10 min before ischemia greatly reduces infarct size in the rabbit heart. These are the first data indicating that direct opening of mitochondrial KATP channels by diazoxide can mimic the anti-infarct effect of ischemic preconditioning. Garlid et al. (9) utilized 30 µM diazoxide to protect isolated rat hearts. Consequently, the present study used a dose of 10 mg/kg. If diazoxide distributes in total body water, then a dose of 10 mg/kg would yield an approximate plasma concentration of 40 µM, which should, therefore, be protective. We did not test whether lower doses would still provide a similar degree of protection. Protection was also observed in isolated rabbit ventricular myocytes exposed to diazoxide. These data confirm the recent observations of Liu et al. (23), who also showed that diazoxide reduced osmotic fragility in rabbit myocytes subjected to 2 h of simulated ischemia. The link between mitochondrial KATP channels and osmotic fragility is enigmatic. An improved energetic state seems unlikely because preserved cytosolic ATP is not a feature of the preconditioned rabbit cardiomyocyte model (1).
If opening of these K+ channels is
indeed the end step in the mechanism of preconditioning, then it could
be reasoned that diazoxide should still exert a protective effect if
given after the onset of ischemia because the delay associated
with the upstream signal transduction pathway would be bypassed.
However, when diazoxide was administered 5 min into the 30-min
ischemia, a decrease in infarct size was no longer observed.
This is probably because collateral flow is very low (~5
ml · min
1 · 100 g tissue1) in the rabbit.
For example, if we apply a simple first-order wash-in model
[halftime = time to achieve 50% concentration = (100 × 0.69)/flow rate], it can be calculated that diazoxide would enter
the ischemic zone with a half-time of 14 min, i.e., very slowly. At the
end of the 30-min ischemic insult, tissue concentration would have
reached only ~78% of that in plasma. Obviously, the drug must have
arrived too late and in too small an amount to produce any beneficial
effect in the posttreatment group. Whether this schedule might be
beneficial in a model with a higher collateral flow such as a dog is
unknown. In a dog in which collateral flow averages 20 ml · min1 · 100 g tissue1, drug would reach
the heart with a half-time of only 3.5 min.
To confirm that diazoxide was indeed acting through mitochondrial KATP channels, we tested whether 5-HD could inhibit the reduction in infarct size. 5-HD has been shown to reverse diazoxide-induced mitochondrial K+ flux (9). This inhibition is dependent on the presence of ATP, Mg2+, and a physiological or pharmacological opener such as diazoxide (19). Increases in mitochondrial redox state in response to diazoxide can also be prevented with this blocker (23). However, 5-HD does not affect sarcolemmal KATP channels (26, 32; unpublished results with rabbit cardiomyocytes). Therefore, 5-HD appears to selectively block mitochondrial KATP channels, and, as expected, pretreatment with 5 mg/kg 5-HD completely abolished the protective effect of diazoxide in the intact rabbit heart.
Diazoxide is a potent vasodilator (9, 30) and is used clinically as an antihypertensive agent. In the anesthetized rabbits, diazoxide elicited a 25-mmHg reduction in mean arterial blood pressure. Such a modest reduction in driving pressure should not have preconditioned the heart because in a previous study we lowered the rabbit's systemic pressure to 41 mmHg with the A2-selective adenosine analog CGS-21680 with no sign of protection (39). In addition, as noted above, diazoxide also protected isolated myocytes as well as isolated rat hearts (9) in which hypotension was not a complicating factor, suggesting that the infarct-reducing effect of the KATP opener is not dependent on any hemodynamic alteration.
It might also be argued that in lieu of a specific effect of 5-HD on
mitochondrial channels the tachycardia induced by the combination of
diazoxide and 5-HD could have contributed to the increase in infarction
in this group. However, in a previous study from our laboratory,
injection of the norepinephrine precursor tyramine caused an elevation
in heart rate similar to that seen in the present study, but in fact
reduced infarct size (38). This protective effect was mediated by
1-receptors. Therefore, increased heart rate per se does not exacerbate ischemic injury in the
anesthetized rabbit.
Previous studies have strongly implicated a role for p38 MAP kinase in ischemic preconditioning in the rabbit (41, 43). Furthermore, anisomycin, which activates MAP kinase kinases 3, 4, 6, and 7 and hence the p38 MAP kinase and JNK pathways, mimics preconditioning in isolated rabbit hearts and myocytes (3, 43). Intravenous injection of 50 µg/kg anisomycin, which would approximate the concentration used in vitro (3), 10 min before ischemia was able to reduce infarct size in the in situ rabbit model. Doubling the dose offered no additional protection. Pretreatment with anisomycin before simulated ischemia was just as protective as ischemic preconditioning in the isolated ventricular myocytes. If stress-activated MAP kinases truly are involved in the mechanism of ischemic preconditioning, then protection elicited by direct activation of p38 MAP kinase/JNK should also be dependent on mitochondrial KATP channels, which seem to be so important in preconditioning. In the present study, 5-HD completely blocked the protective effects of anisomycin in both the anesthetized rabbits and the isolated myocytes. Therefore, like the protection mediated by both diazoxide and ischemic preconditioning, that induced by anisomycin is also sensitive to 5-HD. This confirms that anisomycin is stimulating the same signaling pathway used in ischemic preconditioning and supports the hypothesis that p38 MAP kinase and/or JNK plays an important role in ischemic preconditioning in the rabbit heart.
The involvement of p38 MAP kinase would suggest that changes in the cytoskeleton may also be involved in cardioprotection because activation of the p38 MAP kinase pathway ultimately leads to the serine phosphorylation of HSP27 via the action of MAPKAPK2 (5, 31, 36). The phosphorylated form of HSP27 can act as an end cap, thus stabilizing actin filaments, and can even promote actin polymerization (21). Guay et al. (16) have shown that activation of the p38 MAP kinase pathway greatly increased phosphorylation of HSP27 in CCL39 cells and prevented the disruption of actin filaments by cytochalasin D. Overexpression of HSP27 in these cells also conferred cytoskeletal stability against either cytochalasin or hydrogen peroxide (16, 18). Importantly, increased expression of HSP27 in rat myocytes rendered them resistant to simulated ischemia (24).
In the present investigation, cytochalasin D, which would oppose actin filament polymerization, abolished the reduction in osmotic fragility seen with preconditioning in rabbit myocytes but was without effect in control cells. Therefore, modulation of the actin cytoskeleton appears to be a necessary step in this mechanism. Unexpectedly, cytochalasin D was also able to prevent protection by the direct KATP openers pinacidil and diazoxide. These data suggest that changes in actin filaments and opening of mitochondrial KATP channels may somehow be linked in ischemic preconditioning. Previously, Terzic and Kurachi (37) reported that disruption of actin filaments could reverse ATP-induced inhibition of sarcolemmal KATP channels. This would imply that disruption of actin opens these channels, thus contrasting with our conclusion. However, the opposite was seen in guinea pig myocyte patches in which cytochalasin D induced KATP-channel rundown, which could be reversed with application of purified F-actin and MgATP (6). Therefore, the integrity of the cytoskeleton can markedly influence the activity of at least sarcolemmal KATP channels, but whether cytoskeletal disruption results in opening or closing of the channel is still controversial. There have been no studies examining effects of cytochalasin directly on mitochondrial channels. It is conceivable that ischemic preconditioning preserves actin filaments during ischemia by activation of the p38 MAP kinase/HSP27 pathway. This in turn may initiate and maintain opening of mitochondrial KATP channels with ultimate salvage of cell integrity.
It still is not clear why opening of mitochondrial KATP channels is cardioprotective. Opening would cause a net influx of K+, which should increase matrix volume (8), dissipate energy, and uncouple oxidative phosphorylation. This may be beneficial in ischemia by preventing wasteful ATP hydrolysis (9) and reducing the electrical gradient favoring Ca2+ influx into mitochondria (23).
In conclusion, activation of mitochondrial KATP channels by diazoxide reduces infarct size and protects isolated rabbit myocytes. Disruption of the actin cytoskeleton blocks the protection mediated by both ischemic preconditioning and diazoxide, suggesting that cardioprotection in the rabbit heart requires a coupling between mitochondrial KATP channels and actin filaments.
| |
ACKNOWLEDGEMENTS |
|---|
This study was supported by National Heart, Lung, and Blood Institute Grants HL-20648 and HL-50688.
| |
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: J. M. Downey, MSB 3024, Department of Physiology, College of Medicine, University of South Alabama, Mobile, AL 36688-0002 (E-mail: jdowney{at}usamail.usouthal.edu).
Received 11 September 1998; accepted in final form 11 January 1999.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Armstrong, S.,
and
C. E. Ganote.
Preconditioning of isolated rabbit cardiomyocytes: effects of glycolytic blockade, phorbol esters, and ischaemia.
Cardiovasc. Res.
28:
1700-1706,
1994
2.
Auchampach, J. A.,
G. J. Grover,
and
G. J. Gross.
Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate.
Cardiovasc. Res.
26:
1054-1062,
1992
3.
Baines, C. P.,
L. Wang,
M. V. Cohen,
and
J. M. Downey.
Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart.
J. Mol. Cell. Cardiol.
30:
383-392,
1998[Medline].
4.
Critz, S. D.,
G.-S. Liu,
M. Chujo,
and
J. M. Downey.
Pinacidil but not nicorandil opens ATP-sensitive K+ channels and protects against simulated ischemia in rabbit myocytes.
J. Mol. Cell. Cardiol.
29:
1123-1130,
1997[Medline].
5.
Freshney, N. W.,
L. Rawlinson,
F. Guesdon,
E. Jones,
S. Cowley,
J. Hsuan,
and
J. Saklatvala.
Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27.
Cell
78:
1039-1049,
1994[Medline].
6.
Furukawa, T.,
T.-I. Yamane,
T. Terai,
Y. Katayama,
and
M. Hiraoka.
Functional linkage of the cardiac ATP-sensitive K+ channel to the actin cytoskeleton.
Pflügers Arch.
431:
504-512,
1996[Medline].
7.
Ganote, C.,
and
S. Armstrong.
Ischaemia and the myocyte cytoskeleton: review and speculation.
Cardiovasc. Res.
27:
1387-1403,
1993
8.
Garlid, K. D.
Cation transport in mitochondria: the potassium cycle.
Biochim. Biophys. Acta
1275:
123-126,
1996[Medline].
9.
Garlid, K. D.,
P. Paucek,
V. Yarov-Yarovoy,
H. N. Murray,
R. B. Darbenzio,
A. J. D'Alonzo,
N. J. Lodge,
M. A. Smith,
and
G. J. Grover.
Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels: possible mechanism of cardioprotection.
Circ. Res.
81:
1072-1082,
1997
10.
Garlid, K. D.,
P. Paucek,
V. Yarov-Yarovoy,
X. Sun,
and
P. A. Schindler.
The mitochondrial KATP channel as a receptor for potassium channel openers.
J. Biol. Chem.
271:
8796-8799,
1996
11.
Goto, M.,
Y. Liu,
X.-M. Yang,
J. L. Ardell,
M. V. Cohen,
and
J. M. Downey.
Role of bradykinin in protection of ischemic preconditioning in rabbit hearts.
Circ. Res.
77:
611-621,
1995
12.
Gross, G. J.,
and
J. A. Auchampach.
Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.
Circ. Res.
70:
223-233,
1992
13.
Grover, G. J.
Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion.
Can. J. Physiol. Pharmacol.
75:
309-315,
1997[Medline].
14.
Grover, G. J.,
A. J. D'Alonzo,
T. Hess,
P. G. Sleph,
and
R. B. Darbenzio.
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Cardiovasc. Res.
30:
731-738,
1995[Medline].
15.
Grover, G. J.,
A. J. D'Alonzo,
C. S. Parham,
and
R. B. Darbenzio.
Cardioprotection with KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
J. Cardiovasc. Pharmacol.
26:
145-152,
1995[Medline].
16.
Guay, J.,
H. Lambert,
G. Gingras-Breton,
J. N. Lavoie,
J. Huot,
and
J. Landry.
Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27.
J. Cell Sci.
110:
357-368,
1997[Abstract].
17.
Hide, E. J.,
and
C. Thiemermann.
Limitation of myocardial infarct size in the rabbit by ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate.
Cardiovasc. Res.
31:
941-946,
1996[Medline].
18.
Huot, J.,
F. Houle,
D. R. Spitz,
and
J. Landry.
HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress.
Cancer Res.
56:
273-279,
1996
19.
Jab
rek, M.,
V. Yarov-Yarovoy,
P. Paucek,
and
K. D. Garlid.
State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate.
J. Biol. Chem.
273:
13578-13582,
1998
20.
Kim, S. O.,
B. Salh,
S. L. Pelech,
G. Wong,
and
S. Katz.
Activation of MAPKAP kinase-2 by adenosine in rat heart.
J. NIH Res.
9:
54,
1997.
21.
Landry, J.,
and
J. Huot.
Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27.
Biochem. Cell Biol.
73:
703-707,
1995[Medline].
22.
Liu, G. S.,
J. Thornton,
D. M. Van Winkle,
A. W. H. Stanley,
R. A. Olsson,
and
J. M. Downey.
Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.
Circulation
84:
350-356,
1991
23.
Liu, Y.,
T. Sato,
B. O'Rourke,
and
E. Marban.
Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?
Circulation
97:
2463-2469,
1998
24.
Martin, J. L.,
R. Mestril,
R. Hilal-Dandan,
L. L. Brunton,
and
W. H. Dillmann.
Small heat shock proteins and protection against ischemic injury in cardiac myocytes.
Circulation
96:
4343-4348,
1997
25.
Maulik, N.,
M. Watanabe,
Y.-L. Zu,
C.-K. Huang,
G. A. Cordis,
J. A. Schley,
and
D. K. Das.
Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts.
FEBS Lett.
396:
233-237,
1996[Medline].
26.
McCullough, J. R.,
D. E. Normandin,
M. L. Conder,
P. G. Sleph,
S. Dzwonczyk,
and
G. J. Grover.
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate.
Circ. Res.
69:
949-958,
1991
27.
Miki, T.,
M. V. Cohen,
and
J. M. Downey.
Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits.
Mol. Cell. Biochem.
186:
3-12,
1998[Medline].
28.
Mizumura, T.,
K. Nithipatikom,
and
G. J. Gross.
Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs.
Cardiovasc. Res.
32:
274-285,
1996
29.
Ping, P.,
J. Zhang,
Y. Qiu,
X.-L. Tang,
S. Manchikalapudi,
X. Cao,
and
R. Bolli.
Ischemic preconditioning induces selective translocation of protein kinase C isoforms 
and 
in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity.
Circ. Res.
81:
404-414,
1997
30.
Quast, U.,
and
N. S. Cook.
In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
J. Pharmacol. Exp. Ther.
250:
261-271,
1989
31.
Rouse, J.,
P. Cohen,
S. Trigon,
M. Morange,
A. Alonso-Llamazares,
D. Zamanillo,
T. Hunt,
and
A. R. Nebreda.
A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins.
Cell
78:
1027-1037,
1994[Medline].
32.
Sato, T.,
B. O'Rourke,
and
E. Marbán.
Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C.
Circ. Res.
83:
110-114,
1998
33.
Schultz, J. E. J.,
Y. Z. Qian,
G. J. Gross,
and
R. C. Kukreja.
The ischemia-selective KATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart.
J. Mol. Cell. Cardiol.
29:
1055-1060,
1997[Medline].
34.
Schulz, R.,
J. Rose,
and
G. Heusch.
Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine.
Am. J. Physiol.
267 (Heart Circ. Physiol. 36):
H1341-H1352,
1994
35.
Speechly-Dick, M. E.,
G. J. Grover,
and
D. M. Yellon.
Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model.
Circ. Res.
77:
1030-1035,
1995
36.
Stokoe, D.,
K. Engel,
D. G. Campbell,
P. Cohen,
and
M. Gaestel.
Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins.
FEBS Lett.
313:
307-313,
1992[Medline].
37.
Terzic, A.,
and
Y. Kurachi.
Actin microfilament disrupters enhance KATP channel opening in patches from guinea-pig cardiomyocytes.
J. Physiol. (Lond.)
492:
395-404,
1996[Medline].
38.
Thornton, J. D.,
J. F. Daly,
M. V. Cohen,
X.-M. Yang,
and
J. M. Downey.
Catecholamines can induce adenosine receptor-mediated protection of the myocardium but do not participate in ischemic preconditioning in the rabbit.
Circ. Res.
73:
649-655,
1993
39.
Thornton, J. D.,
G. S. Liu,
R. A. Olsson,
and
J. M. Downey.
Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction.
Circulation
85:
659-665,
1992
40.
Toombs, C. F.,
T. L. Moore,
and
R. J. Shebuski.
Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.
Cardiovasc. Res.
27:
617-622,
1993
41.
Trammell, B. W.,
S. Pain,
J. M. Downey,
M. V. Cohen,
and
S. D. Critz.
MAPKAPK2 is activated in preconditioned rabbit heart (Abstract).
J. Mol. Cell. Cardiol.
30:
A265,
1998.
42.
Walsh, R. S.,
A. Tsuchida,
J. J. F. Daly,
J. D. Thornton,
M. V. Cohen,
and
J. M. Downey.
Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium.
Cardiovasc. Res.
28:
1337-1341,
1994
43.
Weinbrenner, C.,
G.-S. Liu,
M. V. Cohen,
and
J. M. Downey.
Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart.
J. Mol. Cell. Cardiol.
29:
2383-2391,
1997[Medline].
44.
Yao, Z.,
and
G. J. Gross.
Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs.
Circulation
89:
1769-1775,
1994
45.
Ytrehus, K.,
Y. Liu,
and
J. M. Downey.
Preconditioning protects ischemic rabbit heart by protein kinase C activation.
Am. J. Physiol.
266 (Heart Circ. Physiol. 35):
H1145-H1152,
1994
46.
Ytrehus, K.,
Y. Liu,
A. Tsuchida,
T. Miura,
G. S. Liu,
X.-M. Yang,
D. Herbert,
M. V. Cohen,
and
J. M. Downey.
Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing.
Am. J. Physiol.
267 (Heart Circ. Physiol. 36):
H2383-H2390,
1994
This article has been cited by other articles:
|
|
 |
|
  Y. Wu, H. Wang, D. L. Brautigan, and Z. Liu Activation of glycogen synthase in myocardium induced by intermittent hypoxia is much lower in fasted than in fed rats Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E469 - E475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Bernstein, H. Chen, J. A. Boyle, and J. R. Bamburg Formation of actin-ADF/cofilin rods transiently retards decline of mitochondrial potential and ATP in stressed neurons Am J Physiol Cell Physiol, November 1, 2006; 291(5): C828 - C839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mabanta, P. Valane, J. Borne, and M. D. Frame Initiation of remote microvascular preconditioning requires KATP channel activity Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H264 - H271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okada, H. Otani, Y. Wu, S. Kyoi, C. Enoki, H. Fujiwara, T. Sumida, R. Hattori, and H. Imamura Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2310 - H2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nishizawa, P. E. Wolkowicz, T. Yamagishi, L.-L. Guo, and M. M. Pike Fasudil prevents KATP channel-induced improvement in postischemic functional recovery Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H3011 - H3015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kohro, Q. H. Hogan, D. C. Warltier, and Z. J. Bosnjak Protein Kinase C Inhibitors Produce Mitochondrial Flavoprotein Oxidation in Cardiac Myocytes Anesth. Analg., November 1, 2004; 99(5): 1316 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C Kukreja, R. Ockaili, F. Salloum, and L. Xi Sildenafil-induced cardioprotection in rabbits Cardiovasc Res, December 1, 2003; 60(3): 700 - 701. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ichinose, H. Yonemochi, T. Sato, and T. Saikawa Diazoxide triggers cardioprotection against apoptosis induced by oxidative stress Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2235 - H2241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Peart and J. P Headrick Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects Cardiovasc Res, June 1, 2003; 58(3): 589 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Baumann, S. Poitry, A. Roatti, and A. J. Baertschi Plasmalemmal KATP channels shape triggered calcium transients in metabolically impaired rat atrial myocytes Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2296 - H2305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Schwartz, T. S. Welch, and M. S. Crago Cardioprotection by multiple preconditioning cycles does not require mitochondrial KATP channels in pigs Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1538 - H1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Riess, A. K. S. Camara, Q. Chen, E. Novalija, S. S. Rhodes, and D. F. Stowe Altered NADH and improved function by anesthetic and ischemic preconditioning in guinea pig intact hearts Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H53 - H60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohnuma, T. Miura, T. Miki, M. Tanno, A. Kuno, A. Tsuchida, and K. Shimamoto Opening of mitochondrial KATP channel occurs downstream of PKC-epsilon activation in the mechanism of preconditioning Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H440 - H447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Szewczyk and L. Wojtczak Mitochondria as a Pharmacological Target Pharmacol. Rev., March 1, 2002; 54(1): 101 - 127. |
